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Background: Several clinical and pathological factors have an impact on the prognosis of colorectal cancer (CRC),
but they are not yet adequate for risk assessment. We aimed to identify a molecular signature that can reliably
identify CRC patients at high risk for recurrence.
Results: Two hundred eighty-one CRC samples (stage II/III) were included in this study. A two-step gene expression
profiling study was conducted. First, gene expression measurements from 81 fresh frozen CRC samples were obtained
using Affymetrix Human Genome U133 Plus 2.0 Arrays. Second, a focused gene expression assay, including prognostic
genes and genes of interest from literature reviews, was performed using 200 fresh frozen samples and a Taqman
low-density array (TLDA) analysis. An optimal 31-gene expression classifier for the prediction of recurrence among
patients with stage II/III CRC was developed using logistic regression analysis. This gene expression signature classified
58.5% of patients as low-risk and 41.5% as high-risk (P < 0.001). The signature was the strongest independent prognostic
factor in the multivariate analysis. The five-year relapse-free survival (RFS) rates for the low-risk patients and the high-risk
patients were 88.5% and 41.3% (P < 0.001), respectively.
Conclusion: We identified a 31-gene expression signature that is closely associated with the clinical outcome of stage
II/III CRC patients.
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Colorectal cancer (CRC) is the third most common type
of cancer, with a worldwide annual incidence of over 1.2
million cases and a mortality rate of approximately 50%
[1,2]. The growing awareness that CRC is a heteroge-
neous disease with respect to clinical behavior and prog-
nosis translates into an urgent need for robust molecular
subclassifiers in addition to the current parameters. To
date, some clinical and pathologic features, such as in-
testinal perforation/obstruction, adjacent organ involve-
ment (T4), high tumor grade, lymphatic/vascular invasion
and inadequate sampling of lymph nodes, can identify a
minority of CRC patients who are at a high risk of* Correspondence: dx2008cn@163.com
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unless otherwise stated.recurrence [3,4]. However, these prognostic factors are all
relatively weak.
To address this issue, the prognostic potential of mo-
lecular markers, including chromosome and microsatel-
lite instability (MSI) and the mutation status of the
KRAS or BRAF genes, has been systematically investi-
gated in CRC [5-8]. Thus far, only KRAS mutation ana-
lysis has been used in clinical practice as a predictive
marker of the effect of EGFR antibodies in metastatic
disease [5,9]. Analyses of other known critical CRC mo-
lecular markers are not currently recommended for
screening or for prognostic prediction because they re-
quire further validation.
With the recent advent of microarray technology, risk
assessment for CRC has been improved by the use of
gene expression profiling. DNA microarray technology
can measure thousands of mRNA transcripts at once
and may be able to describe the complex biology of a
tumor more accurately than single markers [10,11]. In
the current study, we used gene expression analysis dataThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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identify differentially expressed probes. To further valid-
ate gene expression, we selected 48 genes that could be
assayed using a TaqMan low-density array (TLDA), a
real time quantitative PCR (RT-qPCR) based technology,
using fresh frozen CRC tissues.
Patients and methods
Patients and tumor samples
Samples were prospectively collected between 2007 and
2009 at Fudan University Shanghai Cancer Center. The
inclusion criteria were as follows: primary sporadic colo-
rectal adenocarcinoma (excluding familial adenomatous
polyposis (FAP) and hereditary nonpolyposis colorectal
cancer (HNPCC)), 18 to 75 years of age, no preoperative
chemotherapy and radiotherapy, and similar postopera-
tive chemotherapy regimens. The patients were staged
according to the American Joint Committee on Cancer/
International Union against Cancer (AJCC/UICC) TNM
staging system- seventh edition (2010). Histologic grad-
ing (differentiation) was based on the WHO classifica-
tion of tumors of the digestive system-fourth edition
(2010). This study was approved by the EthicalTable 1 Gene expression assays used for configuring the Taq
























230135_at GENE24 AID1TYDCommittee of our Cancer Center, and written informed
consent was obtained from each patient.
Microarray gene expression profiling
Tumor tissues were taken from 81 patients with CRC,
rapidly frozen in RNAlater, and stored at −80°C until
processing. All samples were visually inspected by two
pathologists, who confirmed the presence of tumor cells
(≥70%) in all samples. RNA was isolated using Trizol
(Life Technologies, Carlsbad, California, USA) and puri-
fied using RNeasy MinElute Cleanup Kit (QIAGEN, Hil-
den, Germany) as recommended by the manufacturers.
Quantity and quality measurements were carried out using
a NanoVue™ Plus Spectrophotometer (GE, London, UK)
and an Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, California, USA). Gene expression profiles
were determined using Affymetrix HG-U133 Plus 2.0
GeneChips according to the recommendations of the
manufacturer.
TaqMan low density array (TLDA)
Two hundred fresh frozen CRC samples were used for
TLDA analysis. Pre-designed TaqMan probe and primerman low-density array card
























Figure 1 Gross appearance and microscopic findings of colorectal cancer. (A), Gross morphology of an opened Miles’ abdominoperineal
resection specimen containing an exophytic mass. The bowel lumen can become progressively narrowed and constricted. (B), Representative
images of a moderately differentiated colorectal adenocarcinoma (H&E stains, ×100). The tumor cells are arranged in glandular patterns, with a
prominent desmoplastic stromal response.
Wang et al. Molecular Cancer  (2015) 14:22 Page 3 of 10sets for target genes were chosen from an online catalog
(Applied Biosystems). Once selected, the primer sets
were factory loaded into the 384 wells of TLDA cards.
Each TLDA card in this study was configured into 8
identical 48-gene sets (2 samples in duplicate). In our
study, 48 genes were chosen based on gene expression
profiling analysis and literature reviews [3,12-22]
(Table 1). Each set contained GAPDH, UBC, and 18S, all
of which were used as reference genes for normalization
[23,24]. These genes were demonstrated to be expressed
in colorectal tissues with little variability. The geometric
mean was used for the calculation of the expression of
target genes.Figure 2 Hierarchical cluster analysis of colorectal cancer (26 recurren
here in matrix format, in which the rows represent individual genes (31 pro
(“D” = death; “R” = relapse; “F” = survival). The red and green colors reflect hTotal RNA was reverse-transcribed using the High-
Capacity cDNA Reverse Transcription Kit using reaction
volumes of 10 μL (Applied Biosystems, Foster City, CA).
A total of 100 μL reaction mixture containing 9 μL of
cDNA template (corresponding to 100 ng of mRNA)
and 50 μL of 2× TaqMan Universal PCR Master Mix
(Applied Biosystems, Foster City, CA, USA) was added
to each line of TLDA after vortex and brief centrifuga-
tion. One microliter of the reaction mixture, which con-
tained 1 ng of mRNA, was transferred to each reaction
cell. The TLDA plates were sealed with a TLDA sealer
before centrifugation in a Thermo Scientific Sorvall
ST40 centrifuge. PCR amplification was carried out int patients vs. 49 non-recurrent patients). The data are presented
bes sets) and the columns represent each tissue from CRC patients
igh and low expression levels, respectively.
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7900HT sequence detection system (Applied Biosystems,
Foster City, CA, USA). The amplification protocol was
as follows: 10 min at 94.5°C (activation), 40 cycles of de-
naturation at 95°C for 15 s, and annealing and extension
at 59.7°C for 1 min.Statistics
The gene expression data were filtered and normalized
using Expression Console™ 1.2.0.20 software to remove
systematic technical variation before further analysis.
Raw data had been deposited in the Gene Expression
Omnibus (GEO) database and were accessible through
the accession number GSE64857. To reduce variation
between individual microarrays, the intensity values for
the samples in each microarray were rescaled by means
of a quantile normalization method. Each intensity value
was log-transformed to a base-2 scale. The intensity
value was coded as 1 for expression levels ranked at orTable 2 mRNA expression in the recurrent group and











PTGS2 0.485 0.011 GENE24 0.835 >0.05
TAF11 1.048 >0.05 DEPDC1 0.323 0.0001
GENE3 1.034 >0.05 LOC400713 2.280 0.0419
NDRG1 1.114 >0.05 LOC253264 1.436 >0.05
STMN2 0.994 >0.05 GENE28 1.049 >0.05
SCG5 0.938 >0.05 GENE29 0.346 0.006
PLK4 1.166 >0.05 GENE30 0.836 >0.05
GENE8 N/A N/A GENE31 N/A >0.05
TNFRSF11B 1.049 >0.05 LOC730102 1.159 >0.05
MMP3 1.102 >0.05 C9orf116 1.003 >0.05
UBD 1.005 >0.05 VEGFA 1.228 >0.05
PROS1 0.774 >0.05 CD44 1.031 >0.05
AKR1C2 1.383 >0.05 MMP2 0.654 0.0216
NUP210 0.655 0.0224 TIMP1 2.153 0.0199
LOC339524 1.019 >0.05 MMP9 0.522 0.0018
C5orf23 0.691 >0.05 CDH1 0.712 0.0071
PBK 0.539 0.0028 VEGFC 1.013 >0.05
GENE18 0.617 0.0317 CTNNB1 1.007 >0.05
BRIP1 1.052 >0.05 GADD45B 1.881 0.041
MEG3 2.236 0.0436 MYBL2 1.398 0.041
CDCA2 0.556 0.0011 IGF2R 0.703 0.0278
RGL3 1.903 0.0435 NME1 1.174 >0.05
SPATA18 0.754 >0.05
*: fold change, the ratio of gene expression in the recurrent group and the
non-recurrent group. Bold text denotes P<0.05.below the 25th percentile of total gene expression, 2 for
levels above the 25th percentile and at or below the 50th
percentile, 3 for levels above the 50th percentile and at
or below the 75th percentile, and 4 for levels above the
75th percentile [25].
The threshold cycle (Ct) generated from TLDA ana-
lysis was automatically determined using the SDS2.2
software package. The relative quantities (RQ) were de-
termined using the equation: RQ = 2-ΔΔCt. To reduce
variation between TLDA analyses, the Ct values for sam-
ples on each TLDA card were also rescaled by means of
a quantile normalization method. Each intensity value
was log-transformed to a base-2 scale. The expression
intensities were ranked as 1, 2, 3, and 4. A binary logistic
regression model was performed to discriminate be-
tween the recurrent group and the non-recurrent group
using a stepwise backward conditional procedure, and
probability was set at 0.05 for entry and 0.10 for re-
moval. A patient was classified into the high risk group
if the value was greater than 0.5 or into the low risk
group if the value was less than 0.5.
Further statistical analyses were performed using SPSS
16.0 software, including independent samples t tests, χ2
tests, univariate and multivariate Cox proportional haz-
ards analyses (estimation of HR and the corresponding
95% confidence intervals), and Kaplan-Meier survival
analysis (differences were assessed by log-rank statistics).
For survival analyses, the end-point was relapse-free sur-
vival (RFS), which was defined as the probability that pa-
tients remain free of recurrence (local/regional or
metastatic) as the first event. A two-sided P-value of ≤
0.05 was considered to be significant.Results
Clinicopathologic characteristics
A total of 281 fresh frozen CRC specimens were in-
cluded in the study (Figure 1), and 81 of these tumors
were used for microarray gene expression analysis. Of
these 81 patients, 47 were male and 34 were female. The
patients’ ages ranged from 29 to 75 years (median
56.3 years). The mean follow-up time was 48 months
(range 38–68 months). Twenty-six patients had relapsed
or died at the time of last follow-up. Six patients were lost
to follow-up. The metastatic sites included the liver (n = 9),
lungs (n =4), abdominal sites (n = 2), and other organs.
Two hundred tumors were used for TLDA analysis.
These tumors were obtained from 117 male patients and
83 female patients. The ages of the patients ranged from
32 to 75 years (median 57.4 years). The mean follow-up
time was 48 months (range 36–68 months). Fifty-five pa-
tients relapsed or died at the time of last follow-up. The
metastatic sites included the liver (n = 17), lungs (n =9),
abdominal sites (n = 6), bones (n = 3), and other organs.
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Genome-wide expression data were used to identify
genes that correlate with patient prognosis. Thirty-three
probe sets were selected according to the following cri-
teria: (1) fold change ≥1.5 or ≤0.67; (2) raw gene expres-
sion signal levels above 100 in 60% of the samples; (3)
P ≤ 0.01 (Figure 2). The 33-gene panel was calculated as
follows: y = C+(B1×1…B33×33), P = EXP(y)/(1 + EXP(y)),
where C represents the constant (C = −160.677788) and
B represents the weight coefficient for each gene. The
expression levels of these 33 genes correlated with re-
lapse. The probe sets are summarized in Table 1. The
sensitivity and specificity of this panel are 92.31% and
71.43%, respectively. The Hosmer-Lemeshow (HL) test
showed good fit of the model (P = 1). As a continuous
variable, the genetic signature classified patients into
two groups using 0.5 as a cutoff; group 1 with P < 0.5
represented the non-recurrent patients, and group 2
with P > 0.5 represented the recurrent patients.
TaqMan low density array analysis
The results of microarray analysis prompted us to imple-
ment a TLDA assay with the differentially expressed
probes. In total, 48 genes were chosen for the TLDAFigure 3 mRNA levels of representative genes in the recurrent group
expression was significantly increased in the non-recurrent group compare
significantly increased in the recurrent group. (C), The level of CDH1 was signi
significantly increased in the recurrent group.assay, including 33 candidate genes that are differentially
expressed based on the microarray analysis, 12 relative
genes selected from a literature review, and 3 reference
genes. Forty-six genes (95.8%, 46/48) were successfully
amplified by TLDA. Seventeen genes (PTGS2, NUP210,
PBK, GENE18, MEG3, CDCA2, RGL3, DEPDC1,
LOC400713, GENE29, MMP2, TIMP1, MMP9, CDH1,
GADD45B, MYBL2, and IGF2R) were differentially
expressed in the recurrent group and the non-recurrent
group based on the TLDA results (t test, P < 0.05).
Eleven genes were significantly down-regulated in the
recurrent group, while 6 genes were significantly up-
regulated. Among these 17 genes (17-gene panel), 10 genes
(10-gene panel) were identified from our microarray ana-
lysis, and 7 genes (7-gene panel) that were identified by
other studies were also confirmed. The fold changes of these
genes are summarized in Table 2. The mRNA levels of the
target genes were calculated as 2^ (−ΔCt). Figure 3 shows the
expression of CDCA2, RGL3, CDH1, and MYBL2 in the re-
current group and the non-recurrent group.
The 31-gene signature and survival
As not all of the genes amplified in the TLDA assay, a
logistic regression analysis was performed in two stepsand the non-recurrent group. (A), The level of CDCA2 mRNA
d to the recurrent group. (B), The level of RGL3 mRNA expression was
ficantly increased in the non-recurrent group. (D), The level of MYBL2 was
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full TLDA PCR data were first used to generate the for-
mula; then all 200 samples, including 121 samples with
partial missing data, were imported and entered into the
formula for analysis. Among the 200 patients, 55 were
recurrent, and 145 were non-recurrent. A 31-gene panel
was developed using logistic regression analysis, each
with a new weight coefficient. To compare the predic-
tion performance of the 31-gene, 17-gene, 10-gene, and
7-gene panels, receiver operator characteristic (ROC)
curves were drawn, and the area under the curve (AUC)
was calculated for each ROC curve based on the stand-
ard leave-one-out procedure. The AUC demonstrated
that the predicting performance of the 31-gene panel
was the best one (0.766 vs 0.576 vs 0.499 vs 0.500,
Figure 4). The use of this algorithm resulted in the
separation of two groups, the recurrent group and the
non-recurrent group. One hundred seventeen out of
200 patients (58.5%) were predicted to be non-
recurrent patients (low risk); among these, 106 were
verified as non-recurrent. Eighty-three out of 200 pa-
tients (41.5%) were predicted to be recurrent patients
(high risk); among these, 44 were observed to be re-
current (P < 0.001). The positive predictive value,Figure 4 Receiver operator characteristic (ROC) curve analyses of
the 31-gene, 17-gene, 10-gene, and 7-gene panel. Sensitivity was
plotted on the y-axis, and 1-specificity was plotted on the x-axis. The area
under the curve (AUC) was 0.766, 0.576, 0.499, and 0.500, respectively.sensitivity and specificity of this set were 90.6%, 73.1%
and 80.0%, respectively.
Kaplan-Meier survival curves and the log-rank test
were used to compare the survival differences between
the two groups. The predicted low-risk group had a lon-
ger RFS than the predicted high-risk group (5-year RFS
88.5% vs. 41.3%, P < 0.001) (Figure 5). When the signa-
ture was separately applied to patients with stage II and
stage III disease, it correctly classified the low- and high-
risk patients in both groups (stage II, 5-year RFS 98.4%
vs. 64.1%, P < 0.001; stage III, 5-year RFS 74.6% vs.
24.4%, P < 0.001). The univariate and multivariate Cox
regression analyses of the clinical parameters and the
31-gene prognostic signature in CRC samples are pro-
vided in Table 3. In the univariate Cox regression ana-
lysis, TNM stage, T stage, N stage, and the prognostic
signature were the strongest predictors of RFS. In the
multivariate analysis, only the prognostic signature was a
strong independent prognostic factor.Discussion
CRC is a heterogeneous disease. Even in patients with
similar pathological and clinical features, the outcome
varies; some are cured, but the cancer recurs in others.
Although official guidelines give suggestions for risk
stratification, there are no clear recommendations for
the administration of adjuvant chemotherapy [26,27].
The staging systems for CRC may have reached their
limit of usefulness for predicting outcomes, but molecu-
lar methods add value. In the present study, we devel-
oped a 31-gene expression signature for the prediction
of relapse among patients with stage II/III CRC based
on the combined use of gene expression profiling and
TLDA analysis. The identification of 31 genes that are
closely associated with outcomes in patients with CRC
has clinical implications. We propose that patients who
have a higher risk of relapse could benefit from adjuvant
therapy and that those who have lower risk could be
spared what may be unnecessary treatment.
In recent years, microarray analyses for the identifica-
tion of differences in gene expression patterns have in-
creased our understanding of the molecular genetic
events in CRC. Several studies have identified gene ex-
pression signatures with a prognostic impact for patients
with stage II and III CRC [11,28-31]. In early studies,
small sample sizes and the lack of validation of inde-
pendent sample sets limited the statistical power of the
conclusions drawn. However, recent publications have
addressed these limitations, and promising gene expres-
sion signatures have been suggested; two promising
prognostic tests based on the expression levels of differ-
ent gene panels have been reported. ColoPrint measures
the expression levels of 18 genes, whereas Oncotype DX
Figure 5 Kaplan-Meier survival curves illustrating relapse-free survival among the recurrent patients and non-recurrent patients.
(A), Stage II, n = 95; the 5-year relapse-free survival rate (RFS) for the low-risk patients was 98.4%, and the 5-year RFS of the high-risk patients was
64.1%. (B), Stage III, n = 105; the 5-year RFS for low-risk patients was 74.6%, and the 5-year RFS for the high-risk patients was 24.4%. (C), All stages,
n = 200; the 5-year RFS for the low-risk patients was 88.5%, and the 5-year RFS for the high-risk patients was 41.3%.
Wang et al. Molecular Cancer  (2015) 14:22 Page 7 of 10includes 12 genes, consisting of 7 recurrence risk genes
and 5 reference genes [3,32]. However, there are few data
points from Chinese patients. In our previous study, an
18-gene signature (CD36, DHRS13, DUSP2, FAM198B,
FKBP5, GLT25D2, GZMB, IL1B, ITGAM, ITPRIPL2,
MYBL1, NEAT1, NUDT16, P2RY10, PDE4D, PDZK1IP1,
SH2D2A, and VSIG10) was identified that could accur-
ately differentiate between peripheral blood samples of
CRC patients and controls. These results open an avenue
for the diagnosis and early detection of CRC [33]. Add-
itional data are needed to develop multi-gene signatures
to predict prognoses of Chinese patients. Based on the
microarray analysis, 33 candidate genes were selected, and
algorithms were developed to identify groups of patients
with high and low risk of recurrence.
In this study, we have shown that TLDA, a robust
methodology based on RT-qPCR, is suitable for the val-
idation of expression profiling of target genes. Hundreds
of reactions can be performed simultaneously, enabling
a large number of samples to be rapidly assessed [34,35].
This technology would be especially useful for identifying
gene signatures with prognostic significance. Gallagher
WM et al. [36] combined the use of DNA microarray and
a tailored TLDA card and identified multiple moleculardeterminants of melanoma progression. In this study, we
have developed a TLDA assay that includes 33 genes that
are differentially expressed in the recurrent group and the
non-recurrent group and 12 relative genes based on a re-
view of the literature. Forty-six genes (95.8%, 46/48) were
successfully amplified by TLDA. Seventeen genes (PTGS2,
NUP210, PBK, GENE18, MEG3, CDCA2, RGL3, DEPDC1,
LOC400713, GENE29, MMP2, TIMP1, MMP9, CDH1,
GADD45B, MYBL2, and IGF2R) were differentially
expressed in the recurrent group and the non-recurrent
group (P < 0.05). Eleven genes were significantly down-
regulated in the recurrent group, while 6 genes were sig-
nificantly up-regulated in the recurrent group. A 31-gene
molecular signature was ultimately developed using logis-
tic regression analysis (PTGS2, TAF11, GENE3, SCG5,
PLK4, TNFRSF11B, MMP3, UBD, AKR1C2, NUP210,
LOC339524, C5orf23, PBK, BRIP1, MEG3, CDCA2, RGL3,
SPATA18, GENE24, LOC400713, LOC253264, CSPP1,
GENE30, C9orf11, CD44, and MMP2). The predicted low-
risk group had a longer RFS than the predicted high-risk
group (5-year RFS 88.5% vs. 41.3%, P < 0.001). When the
signature was separately applied to patients with stage II
and stage III disease, it correctly classified the low- and
high-risk patients in both groups. A range of molecular





P value HR (95% CI) P value HR (95% CI)
Gender 0.303 1.321 (0.778-2.243) 0.940 1.022 (0.571-1.830)
Male 117
Female 83
Age 0.889 0.963 (0.656-1.641) 0.161 0.662 (0.372-1.178)
<60 113
> = 60 87
Tumor size 0.323 1.323 (0.759-2.308) 0.450 1.260 (0.692-2.296)
<5 141
> = 5 59
Location 0.376 0.776 (0.442-1.362) 0.895 0.961 (0.533-1.734)
Colon 77
Rectal 123








Stage <0.001 3.568 (1.912-6.660) 0.701 1.243 (0.410-3.764)
II 95
III 105








Prognostic signature <0.001 7.445 (3.835-14.454) <0.001 6.752 (3.347-13.622)
High risk 83
Low risk 117
Bold text denotes P<0.05.
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The signature was the strongest independent prognostic
factor in the univariate and multivariate analyses.
Our strategy has led to the discovery of recurrence risk
genes that can be confidently associated with clinical
outcome and has confirmed the previously reported as-
sociations of several genes with CRC. PTGS2, orcyclooxygenase 2 (COX2), is the rate-limiting enzyme in
the production of proinflammatory prostaglandins,
which contribute to a pro-angiogenic microenvironment
in tumors [37]. Several studies have demonstrated that
PTGS2 is overexpressed in various tumors, including
CRC [37-39]. Treatment with selective PTGS2 inhibitors
results in reduced colorectal neoplasia risk [40].
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PTGS2 expression and patient survival remain inconclu-
sive. Fux R et al. [41] demonstrated that PTGS2 expres-
sion in tumor epithelial cells is unrelated to overall
survival and to DFS. Tougeron D et al. [42] reported
that aspirin intake is associated with a significant im-
provement in the survival of CRC patients whose tumors
carried mutant but not wild-type copies of the phosphoi-
nositide 3-kinase (PI3KCA) gene. In a study by Aziz A
et al. [43], overexpression of PTGS2 is associated with
better recurrence-free and disease-specific survival in a
large cohort of patients with carcinoma invading bladder
muscle treated by cystectomy. Similarly, in our study,
PTGS2 expression was significantly up-regulated in the
non-recurrent group compared with the recurrent
group. We postulated that PTGS2 overexpression is in-
volved in the initiation stage of carcinogenesis, but after
tumors reach a level of aggressiveness (such as in the
stage II/III cancer cases of the present study), the main-
tenance of PTGS2 expression may be associated with tu-
mors having a better prognosis. The potential of PTGS2
as a prognostic marker in CRC should be considered.
Selected genes of interest in the tumor signature, in-
cluding VEGFA, VEGFC, CD44, CDH1, MMP2, MMP9,
TIMP1, CTNNB1, GADD45B, MYBL2, IGF2R, and
NME1, are known to be involved in angiogenesis, metas-
tasis, and prognosis. Among these genes, MMP2,
TIMP1, MMP9, CDH1, GADD45B, MYBL2, and IGF2R
were differentially expressed in the recurrent group and
the non-recurrent group. To date, the relationships be-
tween MMPs/TIMP expression and patient survival are
controversial. Wong JC [17] reported that MMP2 was
consistently underexpressed in liver metastases com-
pared to primary CRCs. Shorter time to distant metasta-
sis and overall survival occurred in stage III rectal
cancer lacking MMP2. Furthermore, the authors con-
firmed that MMP2 inhibitors promoted cell invasion in
CRC cell lines in vitro. However, Hilska M et al. [44] re-
ported that high expression of MMP2 in the malignant
epithelium and the surrounding stroma was associated
with reduced survival in colon cancer patients. A multi-
variate analysis showed that TIMP3 was the only marker
with an independent prognostic value. In our study, the
expression of MMP2 was down-regulated in the recur-
rent group compared to the non-recurrent group, which
was consistent with the study by Wong JC et al. [17].
The expression of TIMP was up-regulated in the recur-
rent group. Similarly, Fong KM et al. [19] reported
higher levels of TIMP1 RNA in adenocarcinomas, which
are relatively aggressive non-small cell lung cancers, and
observed a striking association between these high levels
and an adverse outcome. Holten-Andersen et al. [45]
showed that high preoperative plasma levels of TIMP1
are associated with short survival in CRC patients.Therefore, instead of inhibiting metastasis, TIMP may
play a role in determining patient survival, possibly by
promoting growth or another function.
Conclusions
In summary, the molecular signature we identified in
this study is closely associated with the clinical outcome
of stage II/III CRC patients. This classifier is based on
the mRNA expression levels of a set of 31 genes and can
be used in a standardized assay for the validation of indi-
vidual patients in a prospective study.
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